| 摘要 |
The invention provides a method for the detection of bladder cancer in a patient comprising assaying a sample from a patient for the levels of at least one combination of biomarkers selected from the combination of i) BTA, CEA and TM, 5 and the combination of ii) NMP22 and EGF, assayed by contacting the sample with a substrate having at least one antibody against each of the biomarkers included in the at least one combination of biomarkers; wherein an increase in levels of the biomarkers in combination i) or an increase in the level of NMP22 and a decrease in the level of EGF in combination ii) compared to a control value indicates bladder 10 cancer in the patient. The invention also provides a solid state device comprising a substrate comprising an antibody to one or more of the biomarkers selected from CEA, BTA, TM, NMP22 and EGF, and a method for determining the efficacy of a drug for treatment of bladder cancer. |
